{"product_id":"blood-and-marrow-transplantation-long-term-management-9781119612698","title":"Blood and Marrow Transplantation Long Term","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003e\u003cb\u003eBlood and Marrow Transplantation Long Term Management\u003c\/b\u003e \u003cp\u003eHematopoietic cell transplantation (HCT) provides curative therapy for a variety of diseases. Over the past several decades, significant advances have been made in the field of HCT, to the point where HCT has become an integral part of treatment modality for a variety of hematologic malignancies and some nonmalignant diseases. HCT remains an important treatment option for a wide variety of hematologic and nonhematologic disorders, despite recent advances in the field of immunologic therapies. Factors driving this growth include expanded disease indications, greater donor options (expanding unrelated donor registries and haploidentical HCT), and accommodation of older and less fit recipients.\u003c\/p\u003e\u003cp\u003eThe development of less toxic pretransplant conditioning regimens, more effective prophylaxis of graft-versus-host disease (GVHD), improved infection control, and other advances in transplant technology have resulted in a rapidly gro\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003e\u003c\/p\u003e\u003cp\u003eForeword by \u003ci\u003eProfessor John Barrett\u003c\/i\u003e vii\u003c\/p\u003e \u003cp\u003eForeword by \u003ci\u003eProfessor John Goldman\u003c\/i\u003e viii\u003c\/p\u003e \u003cp\u003eList of Contributors ix\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSection 1 Late effects concepts 1\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e1 Introduction to long‐term survivorship after hematopoietic cell transplantation 3\u003cbr\u003e\u003ci\u003eBipin N. Savani and André Tichelli\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e2 International Blood and Marrow Registries: trends on long‐term data collection 6\u003cbr\u003e\u003ci\u003eRachel Phelan, Jakob R. Passweg, Helen Baldomero, Minako Iida, Yoshiko Atsuta, Shinichiro Okamoto, Mahmoud Aljurf, Feras Alfraih, and Bronwen E. Shaw\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e3 Long‐term follow‐up program and transplant clinic setup 14\u003cbr\u003e\u003ci\u003eAndré Tichelli, Bipin N. Savani, Shahrukh K. Hashmi, Navneet S. Majhail, and Alicia Rov\u003c\/i\u003e\u003ci\u003eó\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e4 Telemedicine in patient care of long‐term transplant survivors 25\u003cbr\u003e\u003ci\u003eCatherine J. Lee, Mihkaila Wickline, and Mary E.D. Flowers\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e5 Long‐term follow‐up calendar 33\u003cbr\u003e\u003ci\u003eAndré Tichelli, Bipin N. Savani, Shahrukh K. Hashmi, Navneet S. Majhail, and Alicia Rov\u003c\/i\u003e\u003ci\u003eó\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e6 Late effects post‐allogeneic hematopoietic stem cell transplantation 38\u003cbr\u003e\u003ci\u003eShahrukh K. Hashmi and Yoshihiro Inamoto\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e7 Late effects post‐autologous hematopoietic stem cell transplantation 47\u003cbr\u003e\u003ci\u003eRajshekhar Chakraborty and Betty K. Hamilton\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e8 Long‐term follow‐up of children 58\u003cbr\u003e\u003ci\u003ePaul A. Carpenter\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e9 Graft‐versus‐host disease and late effects after hematopoietic stem cell transplantation 73\u003cbr\u003e\u003ci\u003eDavid Michonneau, Aurélien Sutra del Galy, and Gérard Socié\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e10 Screening and prevention guidelines for hematopoietic cell transplant survivors 80\u003cbr\u003e\u003ci\u003eNeel S. Bhatt, J. Douglas Rizzo, and Navneet S. Majhail\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e11 Biology of survivorship after blood or marrow transplantation 92\u003cbr\u003e\u003ci\u003eSmita Bhatia\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSection 2 Specific late effects 101\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e12 Second malignancies 103\u003cbr\u003e\u003ci\u003eAurélien Sutra del Galy, David Michonneau, and Gérard Socié\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e13 Anti‐infective prophylaxis, immunization and prevention of late infectious complications 112\u003cbr\u003e\u003ci\u003ePer Ljungman\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e14 Seasonal respiratory viral infections 119\u003cbr\u003e\u003ci\u003eNosha Farhadfar, Zeina Al‐Mansour, and John R. Wingard\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e15 Monitoring and management of hepatitis B, C, and HIV infection before and after transplantation 132\u003cbr\u003e\u003ci\u003eEnric Carreras and Montserrat Rovira\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e16 Skin chronic GVHD 140\u003cbr\u003e\u003ci\u003eAttilio Olivieri, Anna Campanati, Gaia Goteri, and Andrea Bacigalupo\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e17 Ocular complications 166\u003cbr\u003e\u003ci\u003eAlicia Rov\u003c\/i\u003e\u003ci\u003eó, André Tichelli, and Yoshihiro Inamoto\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e18 Management of oral and dental complications 176\u003cbr\u003e\u003ci\u003eHildegard T. Greinix\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e19 Thyroid disease: monitoring and management guidelines 183\u003cbr\u003e\u003ci\u003eJuliana Matthews, Leslee Matheny, and Shubhuda Jagasia\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e20 Pretransplant considerations in gender, reproductive, and sexual health 189\u003cbr\u003e\u003ci\u003eDana Shanis, Jeanne Murphy, Kate Debiec, Betty K. Hamilton, Shawna Boyle, and Pamela Stratton\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e21 Posttransplant Considerations in Gender, Reproductive, and Sexual Health 198\u003cbr\u003e\u003ci\u003eJeanne Murphy, Dana Shanis, Kate Debiec, Betty K. Hamilton, Shawna Boyle, and Pamela Stratton\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e22 Fertility issues, fertility preservation, and pregnancy outcome in long‐term survivors 211\u003cbr\u003e\u003ci\u003eAlicia Rov\u003c\/i\u003e\u003ci\u003eó, Alison W. Loren, André Tichelli, and Nina Salooja\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e23 Sexual Dysfunction in Long‐Term Survivors 221\u003cbr\u003e\u003ci\u003eRebecca L. Hunter, Sarah Thilges, Janna Gordon, Kristy Luke, Karla Cavazos, Emilee Moeke, Colleen Bruen, and Sunita Nathan\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e24 Late non‐infectious pulmonary complications 231\u003cbr\u003e\u003ci\u003eAyman O. Soubani\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e25 Cardiac and arterial complications 241\u003cbr\u003e\u003ci\u003eAlicia Rov\u003c\/i\u003e\u003ci\u003eó and André Tichelli\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e26 Cardiovascular risk factors 251\u003cbr\u003e\u003ci\u003eKimberley Doucette and Minoo Battiwalla\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e27 Gastrointestinal complications 260\u003cbr\u003e\u003ci\u003eSumona Bhattacharya, Steven Pavletic, and Theo Heller\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e28 Hepatic Complications 271\u003cbr\u003e\u003ci\u003eChristy Ann L. Gilman, Christopher Koh, Steven Pavletic, and Theo Heller\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e29 Renal complications 278\u003cbr\u003e\u003ci\u003eInsara Jaffer Sathick and Sangeeta Hingorani\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e30 Posttransplantation bone disease: prevalence, surveillance, prevention, and management 287\u003cbr\u003e\u003ci\u003eChristine N. Duncan\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e31 Late neurologic complications 300\u003cbr\u003e\u003ci\u003eEnrico Maffini\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e32 Neurocognitive dysfunction 312\u003cbr\u003e\u003ci\u003eDavid Buchbinder and Angela Scherwath\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e33 Psychological Distress 330\u003cbr\u003e\u003ci\u003eAnna Barata, Aasha I. Hoogland, and Heather S. L. Jim\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e34 Evaluation and management of fatigue in survivors of allogeneic hematopoietic stem cell transplantation 337\u003cbr\u003e\u003ci\u003eSandra A. Mitchell\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e35 Social Issues 349\u003cbr\u003e\u003ci\u003eSanghee Hong and Navneet S. Majhail\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e36 Health‐related quality of life in adult and pediatric survivors 355\u003cbr\u003e\u003ci\u003eSandra A. Mitchell, Lori Wiener, Jenny Hoag, Abigail Fry, and Margaret F. Bevans\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSection 3 Supportive care and patients reported outcomes 381\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e37 Immunosuppressive agents and monitoring in long‐term survivors 383\u003cbr\u003e\u003ci\u003eKathryn A. Culos and Katie S. Gatwood\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e38 Nutritional support and nutritional supplementation 393\u003cbr\u003e\u003ci\u003eShigeo Fuji\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e39 Daily routines and healthy lifestyle guidelines 397\u003cbr\u003e\u003ci\u003eMelissa Logue\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e40 Prevalent psychosocial adjustment issues and solutions: lifestyle and social challenges 402\u003cbr\u003e\u003ci\u003eKatrina M. Stokes\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e41 Complementary and alternative medicine in HSCT 406\u003cbr\u003e\u003ci\u003eIbrahim N. Muhsen, Bipin N. Savani,, and Shahrukh K. Hashmi\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e42 Impact of adherence in outcome of long‐term survivors 413\u003cbr\u003e\u003ci\u003eCorien Eeltink and Annika Kisch\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e43 Prominent role of allied health professionals 418\u003cbr\u003e\u003ci\u003eCatherine E. Lucid\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e44 Patient reported outcomes 420\u003cbr\u003e\u003ci\u003eHél\u003c\/i\u003e\u003ci\u003eène Schoemans\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e45 Caregivers of long‐term survivors 428\u003cbr\u003e\u003ci\u003eAngela Moreschi Woods\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e46 Patient’s perspective: memoir of a recovered lymphomaniac 434\u003cbr\u003e\u003ci\u003eMichael Brown\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eAppendix 1 Commonly used transplant‐related medications in long‐term survivors 442\u003cbr\u003e\u003ci\u003eKathryn A. Culos and Katie S. Gatwood\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eAppendix 2 The eGVHD App 445\u003cbr\u003e\u003ci\u003eHél\u003c\/i\u003e\u003ci\u003eène Schoemans\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIndex 448\u003c\/p\u003e","brand":"John Wiley and Sons Ltd","offers":[{"title":"Default Title","offer_id":49407099502935,"sku":"9781119612698","price":124.15,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9781119612698.jpg?v=1730498175","url":"https:\/\/bookcurl.com\/products\/blood-and-marrow-transplantation-long-term-management-9781119612698","provider":"Book Curl","version":"1.0","type":"link"}